{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:14:37Z","timestamp":1761498877399,"version":"build-2065373602"},"reference-count":85,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.beha.2023.101443","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T21:44:55Z","timestamp":1675374295000},"page":"101443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Late effects and frontline treatment selection for children with non-Hodgkin lymphoma"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2781-9983","authenticated-orcid":false,"given":"Matthew J.","family":"Ehrhardt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie B.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Belsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Hochberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2023.101443_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrc3634","article-title":"Survivors of childhood and adolescent cancer: life-long risks and responsibilities","volume":"14","author":"Robison","year":"2014","journal-title":"Nat Rev Cancer"},{"journal-title":"Nat rev clin oncol","year":"2023","author":"Ehrhardt","key":"10.1016\/j.beha.2023.101443_bib2"},{"key":"10.1016\/j.beha.2023.101443_bib3","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1056\/NEJMoa1510795","article-title":"Reduction in late mortality among 5-year survivors of childhood cancer","volume":"374","author":"Armstrong","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2023.101443_bib4","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/S0140-6736(17)31610-0","article-title":"The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE)","volume":"390","author":"Bhakta","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2023.101443_bib5","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2014.59.5827","article-title":"Non-hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead","volume":"33","author":"Minard-Colin","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib6","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1200\/JCO.2004.11.032","article-title":"Development of risk-based guidelines for pediatric cancer survivors: the children's oncology group long-term follow-up guidelines from the children's oncology group late effects committee and nursing discipline","volume":"22","author":"Landier","year":"2004","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib7","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1200\/JCO.19.00525","article-title":"Late health outcomes after contemporary Lymphome Malin de Burkitt therapy for mature B-cell non-Hodgkin lymphoma: a report from the childhood cancer survivor study","volume":"37","author":"Ehrhardt","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib8","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/bjh.15775","article-title":"Long-term survivors of childhood, adolescent and young adult non-Hodgkin lymphoma","volume":"185","author":"Ehrhardt","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2023.101443_bib9","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/cncr.31019","article-title":"Neurocognitive, psychosocial, and quality-of-life outcomes in adult survivors of childhood non-Hodgkin lymphoma","volume":"124","author":"Ehrhardt","year":"2018","journal-title":"Cancer"},{"volume":"vol. 64","year":"2017","author":"Ehrhardt","key":"10.1016\/j.beha.2023.101443_bib10"},{"key":"10.1016\/j.beha.2023.101443_bib11","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1182\/blood-2007-08-106021","article-title":"Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study","volume":"111","author":"Bluhm","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101443_bib12","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41375-020-0841-x","article-title":"Second malignant neoplasms after treatment of non-Hodgkin's lymphoma-a retrospective multinational study of 189 children and adolescents","volume":"35","author":"Attarbaschi","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2023.101443_bib14","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1056\/NEJM198303103081003","article-title":"Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2)","volume":"308","author":"Anderson","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2023.101443_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1200\/JCO.1991.9.1.123","article-title":"High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children","volume":"9","author":"Patte","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib16","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","article-title":"The Soci\u00e9t\u00e9 Fran\u00e7aise d'Oncologie P\u00e9diatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia","volume":"97","author":"Patte","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101443_bib17","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-07-036665","article-title":"Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents","volume":"109","author":"Cairo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101443_bib18","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1365-2141.2008.07144.x","article-title":"Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB\/LMB 96 international study","volume":"141","author":"Gerrard","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2023.101443_bib19","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101443_bib20","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","article-title":"The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia","volume":"97","author":"Patte","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101443_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/08880018609031196","article-title":"High-dose methotrexate and continuous infusion Ara-C in children's non-Hodgkin's lymphoma: phase II studies and their use in further protocols","volume":"3","author":"Patte","year":"1986","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib22","first-page":"3294","article-title":"Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90","volume":"94","author":"Reiter","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101443_bib23","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/pbc.24975","article-title":"Improved treatment results of children with B-cell non-Hodgkin lymphoma: a report from the Japanese Pediatric Leukemia\/Lymphoma Study Group B-NHL03 study","volume":"61","author":"Tsurusawa","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.beha.2023.101443_bib24","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-03-0973","article-title":"The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95","volume":"105","author":"Woessmann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101443_bib25","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-Hodgkin's lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2023.101443_bib26","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.1986.4.12.1732","article-title":"Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine","volume":"4","author":"Murphy","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib27","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/1097-0142(19800215)45:4<630::AID-CNCR2820450403>3.0.CO;2-5","article-title":"A randomized trial of combined modality therapy of childhood non-Hodgkin's lymphoma","volume":"45","author":"Murphy","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2023.101443_bib28","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101443_bib29","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJM199004263221701","article-title":"Results of treatment of childhood localized non-Hodgkin's lymphoma with combination chemotherapy with or without radiotherapy","volume":"322","author":"Link","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2023.101443_bib30","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1056\/NEJM199710303371802","article-title":"Treatment of children and young adults with early-stage non-Hodgkin's lymphoma","volume":"337","author":"Link","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2023.101443_bib31","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.1989.7.1.92","article-title":"Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin's lymphoma of children: a report from the Childrens Cancer Study Group","volume":"7","author":"Meadows","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2023.101443_bib33","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.13040","article-title":"Rituximab with chemotherapy in children and adolescents with central nervous system and\/or bone marrow-positive Burkitt lymphoma\/leukaemia: a Children's Oncology Group Report","volume":"167","author":"Goldman","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2023.101443_bib34","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-Hodgkin's lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2023.101443_bib35","doi-asserted-by":"crossref","first-page":"648","DOI":"10.29271\/jcpsp.2018.08.648","article-title":"Metastatic squamous cell carcinoma versus primary high grade serous carcinoma of the ovary","volume":"28","author":"Zhou","year":"2018","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.beha.2023.101443_bib36","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2012.255","article-title":"Rituximab and FAB\/LMB 96 chemotherapy in children with Stage III\/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report","volume":"27","author":"Goldman","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2023.101443_bib37","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2023.101443_bib38","first-page":"4124","volume":"130","author":"Burke","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101443_bib39","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1200\/JCO.21.00920","article-title":"Dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab therapy in children and adolescents with primary mediastinal B-cell lymphoma: a multicenter phase II trial","volume":"39","author":"Burke","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib40","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2023.101443_bib41","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.14951","article-title":"Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R","volume":"179","author":"Giulino-Roth","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2023.101443_bib42","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jtho.2015.11.009","article-title":"The 2015 WHO classification of tumors of the Heart and pericardium","volume":"11","author":"Burke","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib43","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.3324\/haematol.2021.280257","article-title":"Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study","volume":"107","author":"Dourthe","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2023.101443_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(23)00012-8","article-title":"Systematic review and updated cardiomyopathy surveillance recommendations for survivors of childhood, adolescent, and young adult cancer from the international late effects of childhood cancer guideline harmonization group","author":"Ehrhardt","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib45","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1002\/pbc.25187","article-title":"Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the children's oncology group","volume":"61","author":"Alexander","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.beha.2023.101443_bib46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2005.05735.x","article-title":"The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence","volume":"131","author":"Burkhardt","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2023.101443_bib47","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/jcp.50.2.128","article-title":"Childhood non-Hodgkin lymphomas in the United Kingdom: findings from the UK children's cancer study group","volume":"50","author":"Wright","year":"1997","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.beha.2023.101443_bib48","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood.2020009806","article-title":"Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1","volume":"137","author":"Lowe","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101443_bib49","article-title":"Crizotinib in combination with chemotherapy for pediatric patients with ALK+ anaplastic large-cell lymphoma: the results of children's oncology group trial ANHL12P1","author":"Lowe","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib50","doi-asserted-by":"crossref","first-page":"712","DOI":"10.7326\/M14-2327","article-title":"High value care task force of the American college of P. A value framework for cancer screening: advice for high-value care from the American college of physicians","volume":"162","author":"Harris","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beha.2023.101443_bib51","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.6004\/jnccn.2022.0057","article-title":"Pediatric aggressive mature B-cell lymphomas, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Barth","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.beha.2023.101443_bib52","doi-asserted-by":"crossref","first-page":"81","DOI":"10.6004\/jnccn.2020.0001","article-title":"Pediatric acute lymphoblastic leukemia, version 2.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Brown","year":"2020","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.beha.2023.101443_bib53","doi-asserted-by":"crossref","first-page":"733","DOI":"10.6004\/jnccn.2021.0027","article-title":"Pediatric Hodgkin lymphoma, version 3.2021","volume":"19","author":"Flerlage","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.beha.2023.101443_bib54","doi-asserted-by":"crossref","first-page":"755","DOI":"10.6004\/jnccn.2021.7042","article-title":"Integration of pediatric Hodgkin lymphoma treatment and late effects guidelines: seeing the forest beyond the trees","volume":"19","author":"Ehrhardt","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.beha.2023.101443_bib55","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1089\/jayao.2020.0012","article-title":"Standardizing risk assessment for treatment-related gonadal insufficiency and infertility in childhood adolescent and young adult cancer: the pediatric initiative Network risk stratification system","volume":"9","author":"Meacham","year":"2020","journal-title":"J Adolesc Young Adult Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib56","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2008.18.1487","article-title":"Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group","volume":"27","author":"Brugieres","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib57","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1667\/RR14213.1","article-title":"Thyroid cancer after childhood exposure to external radiation: an updated pooled analysis of 12 studies","volume":"185","author":"Veiga","year":"2016","journal-title":"Radiat Res"},{"key":"10.1016\/j.beha.2023.101443_bib58","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1200\/JCO.20.00562","article-title":"Updated breast cancer surveillance recommendations for female survivors of childhood, adolescent, and young adult cancer from the international guideline harmonization group","volume":"38","author":"Mulder","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib59","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ctrv.2015.12.002","article-title":"Risk of subsequent gastrointestinal cancer among childhood cancer survivors: a systematic review","volume":"43","author":"Teepen","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.beha.2023.101443_bib60","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/pbc.24445","article-title":"A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"60","author":"Kremer","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.beha.2023.101443_bib61","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.beha.2023.101443_bib62","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.beha.2023.101443_bib63","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.beha.2023.101443_bib64","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/S1470-2045(14)70409-7","article-title":"Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the international late effects of childhood cancer guideline harmonization group","volume":"16","author":"Armenian","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib65","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ctrv.2017.11.005","volume":"63","author":"Clement","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.beha.2023.101443_bib66","doi-asserted-by":"crossref","first-page":"e621","DOI":"10.1016\/S1470-2045(13)70303-6","article-title":"Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"14","author":"Mulder","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib67","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S1470-2045(17)30026-8","volume":"18","author":"Skinner","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib68","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1200\/JCO.2015.64.3288","volume":"34","author":"van Dorp","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib69","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28702","article-title":"Guidance regarding COVID-19 for survivors of childhood, adolescent, and young adult cancer: a statement from the international late effects of childhood cancer guideline harmonization group","volume":"67","author":"Verbruggen","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.beha.2023.101443_bib70","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1210\/endrev\/bnab040","article-title":"Hypothalamic-pituitary and other endocrine surveillance among childhood cancer survivors","volume":"43","author":"van Iersel","year":"2022","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beha.2023.101443_bib71","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ajog.2020.05.058","article-title":"Counseling and surveillance of obstetrical risks for female childhood, adolescent, and young adult cancer survivors: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"224","author":"van der Kooi","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.beha.2023.101443_bib72","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejca.2021.06.021","article-title":"Coronary artery disease surveillance among childhood, adolescent and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"156","author":"van Dalen","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.beha.2023.101443_bib73","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S2213-8587(21)00173-X","article-title":"Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"9","author":"van Atteveld","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beha.2023.101443_bib74","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1016\/S1470-2045(20)30595-7","volume":"22","author":"Mulder","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib75","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S1470-2045(20)30594-5","article-title":"Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE consortium and the international late effects of childhood cancer guideline harmonization group","volume":"22","author":"Mulder","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib76","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/S1470-2045(20)30582-9","article-title":"Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE consortium and the international late effects of childhood cancer guideline harmonization group","volume":"22","author":"Mulder","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib77","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1016\/S1470-2045(21)00750-6","article-title":"Recommendations for the surveillance of mental health problems in childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"23","author":"Marchak","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib78","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1002\/cncr.34215","article-title":"Recommendations for the surveillance of education and employment outcomes in survivors of childhood, adolescent, and young adult cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"128","author":"Devine","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2023.101443_bib79","first-page":"CD014638","article-title":"Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines","volume":"9","author":"de Baat","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.beha.2023.101443_bib80","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S1470-2045(18)30858-1","article-title":"Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the international late effects of childhood cancer guideline harmonization group in collaboration with the PanCare consortium","volume":"20","author":"Clemens","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib81","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s11764-020-00904-9","article-title":"Recommendations for the surveillance of cancer-related fatigue in childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"14","author":"Christen","year":"2020","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.beha.2023.101443_bib82","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S1470-2045(20)30688-4","article-title":"Surveillance for subsequent neoplasms of the CNS for childhood, adolescent, and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"22","author":"Bowers","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102296","article-title":"Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: recommendations from the international late effects of childhood cancer guideline harmonization group","volume":"100","author":"Bardi","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.beha.2023.101443_bib84","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","article-title":"Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children's oncology group study","volume":"35","author":"Mosse","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib85","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study","volume":"14","author":"Mosse","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2023.101443_bib86","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1200\/JCO.22.00196","article-title":"We cannot change what we cannot see: a rationale for patient-reported outcomes in pediatric oncology clinical research","volume":"40","author":"Rosenberg","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169262300004X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169262300004X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:07:40Z","timestamp":1761498460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169262300004X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S152169262300004X"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2023.101443","relation":{},"ISSN":["1521-6926"],"issn-type":[{"type":"print","value":"1521-6926"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Late effects and frontline treatment selection for children with non-Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2023.101443","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101443"}}